Glycogen synthase kinase-3 inhibitors: preclinical and clinical focus on CNS-A decade onward
SM Arciniegas Ruiz, H Eldar-Finkelman - Frontiers in molecular …, 2022 - frontiersin.org
The protein kinase, GSK-3, participates in diverse biological processes and is now
recognized a promising drug discovery target in treating multiple pathological conditions …
recognized a promising drug discovery target in treating multiple pathological conditions …
Current and emerging treatment modalities for spinocerebellar ataxias
SD Ghanekar, SH Kuo, JS Staffetti… - Expert review of …, 2022 - Taylor & Francis
Introduction Spinocerebellar ataxias (SCA) are a group of rare neurodegenerative diseases
that dramatically affect the lives of affected individuals and their families. Despite having a …
that dramatically affect the lives of affected individuals and their families. Despite having a …
Pharmacological and non-pharmacological management of spinocerebellar ataxia: a systematic review
Spinocerebellar ataxias (SCA) comprise a rare, genetic subgroup within the degenerative
ataxias and are dominantly inherited, with up to 48 recognized genetic subtypes. While an …
ataxias and are dominantly inherited, with up to 48 recognized genetic subtypes. While an …
The key role of magnetic resonance imaging in the detection of neurodegenerative diseases-associated biomarkers: a review
KR Li, AG Wu, Y Tang, XP He, CL Yu, JM Wu… - Molecular …, 2022 - Springer
Neurodegenerative diseases (NDs), including chronic disease such as Alzheimer's disease,
Parkinson's disease, Huntington's disease, and multiple sclerosis, and acute diseases like …
Parkinson's disease, Huntington's disease, and multiple sclerosis, and acute diseases like …
[HTML][HTML] Bisphosphate nucleotidase 2 (BPNT2), a molecular target of lithium, regulates chondroitin sulfation patterns in the cerebral cortex and hippocampus
Abstract Bisphosphate nucleotidase 2 (BPNT2) is a member of a family of phosphatases that
are directly inhibited by lithium, the first-line medication for bipolar disorder. BPNT2 is …
are directly inhibited by lithium, the first-line medication for bipolar disorder. BPNT2 is …
Placebo response in degenerative cerebellar ataxias: a descriptive review of randomized, placebo-controlled trials
Placebo response in degenerative cerebellar ataxias (CAs) has never been studied despite
the large number of randomized controlled trials (RCTs) that have been conducted. In this …
the large number of randomized controlled trials (RCTs) that have been conducted. In this …
Molecular and clinical determinants of pathogenic protein aggregation: modulation of polyglutamine diseases by molecular chaperones
EP Mattos - 2022 - research.rug.nl
Correct protein folding is essential for life, but in the complex cellular environment proteins
face many risks of misfolding and/or aggregating. Protein aggregation, especially of so …
face many risks of misfolding and/or aggregating. Protein aggregation, especially of so …